Academic Journal
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
| العنوان: | Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma |
|---|---|
| المؤلفون: | Scheiner, Bernhard, Roessler, Daniel, Phen, Samuel, Lim, Mir, Pomej, Katharina, Pressiani, Tiziana, Cammarota, Antonella, Fründt, Thorben W, von Felden, Johann, Schulze, Kornelius, Himmelsbach, Vera, Finkelmeier, Fabian, Deibel, Ansgar, Siebenhüner, Alexander R, Shmanko, Kateryna, Radu, Pompilia, Schwacha-Eipper, Birgit, Ebert, Matthias P, Teufel, Andreas, Djanani, Angela, Hucke, Florian, Balcar, Lorenz, Philipp, Alexander B, Hsiehchen, David, Venerito, Marino, Sinner, Friedrich, Trauner, Michael, D'Alessio, Antonio, Fulgenzi, Claudia A M, Pinato, David J |
| المصدر: | Scheiner, Bernhard; Roessler, Daniel; Phen, Samuel; Lim, Mir; Pomej, Katharina; Pressiani, Tiziana; Cammarota, Antonella; Fründt, Thorben W; von Felden, Johann; Schulze, Kornelius; Himmelsbach, Vera; Finkelmeier, Fabian; Deibel, Ansgar; Siebenhüner, Alexander R; Shmanko, Kateryna; Radu, Pompilia; Schwacha-Eipper, Birgit; Ebert, Matthias P; Teufel, Andreas; Djanani, Angela; Hucke, Florian; Balcar, Lorenz; Philipp, Alexander B; Hsiehchen, David; Venerito, Marino; Sinner, Friedrich; Trauner, Michael; D'Alessio, Antonio; Fulgenzi, Claudia A M; Pinato, David J; et al (2023). Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Reports, 5(1):100620. |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2023 |
| المجموعة: | University of Zurich (UZH): ZORA (Zurich Open Repository and Archive |
| مصطلحات موضوعية: | Clinic for Gastroenterology and Hepatology, 610 Medicine & health |
| الوصف: | BACKGROUND & AIMS: We investigated the efficacy and safety of immune checkpoint inhibitor (ICI) rechallenge in patients with hepatocellular carcinoma (HCC) who received ICI-based therapies in a previous systemic line. METHODS: In this international, retrospective multicenter study, patients with HCC who received at least two lines of ICI-based therapies (ICI-1, ICI-2) at 14 institutions were eligible. The main outcomes included best overall response and treatment-related adverse events. RESULTS: Of 994 ICI-treated patients screened, a total of 58 patients (male, n = 41; 71%) with a mean age of 65.0±9.0 years were included. Median systemic treatment lines of ICI-1 and ICI-2 were 1 (range, 1-4) and 3 (range, 2-9), respectively. ICI-based therapies used at ICI-1 and ICI-2 included ICI alone (ICI-1, n = 26, 45%; ICI-2, n = 4, 7%), dual ICI regimens (n = 1, 2%; n = 12, 21%), or ICI combined with targeted therapies/anti-VEGF (n = 31, 53%; n = 42, 72%). Most patients discontinued ICI-1 due to progression (n = 52, 90%). Objective response rate was 22% at ICI-1 and 26% at ICI-2. Responses at ICI-2 were also seen in patients who had progressive disease as best overall response at ICI-1 (n = 11/21; 52%). Median time-to-progression at ICI-1 and ICI-2 was 5.4 (95% CI 3.0-7.7) months and 5.2 (95% CI 3.3-7.0) months, respectively. Treatment-related adverse events of grade 3-4 at ICI-1 and ICI-2 were observed in 9 (16%) and 10 (17%) patients, respectively. CONCLUSIONS: ICI rechallenge was safe and resulted in a treatment benefit in a meaningful proportion of patients with HCC. These data provide a rationale for investigating ICI-based regimens in patients who progressed on first-line immunotherapy in prospective trials. IMPACT AND IMPLICATIONS: Therapeutic sequencing after first-line immune checkpoint inhibitor (ICI)-based therapy for advanced hepatocellular carcinoma (HCC) remains a challenge as no available second-line treatment options have been studied in immunotherapy-pretreated patients. Particularly, the role of ICI ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2589-5559 |
| Relation: | https://www.zora.uzh.ch/id/eprint/227499/1/ZORA_227499.pdf; info:pmid/36578451; urn:issn:2589-5559 |
| DOI: | 10.1016/j.jhepr.2022.100620 |
| الاتاحة: | https://www.zora.uzh.ch/id/eprint/227499/ https://www.zora.uzh.ch/id/eprint/227499/1/ZORA_227499.pdf https://doi.org/10.1016/j.jhepr.2022.100620 |
| Rights: | info:eu-repo/semantics/openAccess ; Creative Commons: Attribution 4.0 International (CC BY 4.0) ; http://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.344D0652 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 25895559 |
|---|---|
| DOI: | 10.1016/j.jhepr.2022.100620 |